

## Public Summary

Summary for ARTG Entry: 225162 PSC 200

**ARTG entry for** Medicine Listed  
**Sponsor** Tirsol Pty Ltd  
**Postal Address** PO Box 1430, FRANKSTON, VIC, 3199  
Australia  
**ARTG Start Date** 30/06/2014  
**Product category** Medicine  
**Status** Active  
**Approval area** Listed Medicines

## Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

## Products

## 1. PSC 200

Product Type	Single Medicine Product	Effective date	30/06/2014
--------------	-------------------------	----------------	------------

## Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,  
For practitioner dispensing only.

## Standard Indications

Treatment of dry or inflamed skin conditions. [Warning S required],  
For the symptomatic relief of dry skin.,  
May assist in the management of dry skin.

## Specific Indications

No Specific Indications included on Record

## Additional Product information

## Pack Size/Poison information

## Pack Size

## Components

## 1. Formulation 1

## Dosage Form

Tablet, film coated

## Route of Administration

Oral

## Visual Identification

## Active Ingredients

## Allium sativum

50 mg

Equivalent: Allium sativum (Fresh)

1 g

<b>Arctium lappa</b>	<b>7.5 mg</b>
Equivalent: Arctium lappa (Dry)	30 mg
<b>Artemisia annua</b>	<b>7.5 mg</b>
Equivalent: Artemisia annua (Dry)	30 mg
<b>Astragalus membranaceus</b>	<b>32 mg</b>
Equivalent: Astragalus membranaceus (Dry)	160 mg
<b>Berberis vulgaris</b>	<b>36.7 mg</b>
Equivalent: Berberis vulgaris (Dry)	220.2 mg
<b>Echinacea purpurea</b>	<b>30 mg</b>
Equivalent: Echinacea purpurea (Fresh)	1.35 g
<b>Glycyrrhiza glabra</b>	<b>3 mg</b>
Equivalent: Glycyrrhiza glabra (Dry)	12 mg
<b>Hydrastis canadensis</b>	<b>10 mg</b>
Equivalent: Hydrastis canadensis (Dry)	40 mg
<b>Juglans nigra</b>	<b>230 mg</b>
<b>Panax ginseng</b>	<b>14 mg</b>
Equivalent: Panax ginseng (Dry)	140 mg
<b>Taraxacum officinale</b>	<b>40 mg</b>
Equivalent: Taraxacum officinale (Dry)	160 mg
<b>Thymus vulgaris</b>	<b>9.8 mg</b>
Equivalent: Thymus vulgaris (Dry)	68.6 mg

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.